xoma corp said filed registration statement with securities and exchange commission covering proposed public offering mln common shares xoma biotechnology company which produces monoclonal antibody based products treat some forms cancer said proceeds will used fund research and product development human clinical trials and expansion manufacturing capacity and working capital said dillon read and inc and alex brown and sons inc will manage underwriting reuter 